Navigation Links
Remicade(R) Get Approval for First and Only Biologic Treatment for Pediatric Crohn's Disease

an inadequate response to conventional therapy. REMICADE was first approved in the U.S. for adult Crohn's disease in 1998 and later for adult ulcerative colitis in 2005.

The safety and efficacy of REMICADE across all indications have been well established in clinical trials over the past 14 years and through commercial experience with nearly 925,000 patients treated worldwide across all indications.

The label extension will permit physicians to administer a 5 mg/kg intravenous infusion of REMICADE over a 2-hour period followed by additional 5 mg/kg infusion doses at two and six weeks after the first infusion, then every eight weeks thereafter.

Some patients may require a shorter dosing interval to maintain clinical benefit, while for others a longer dosing interval may be sufficient. Available data do not support further REMICADE treatment in pediatric patients not responding within the first 10 weeks of treatment.


'"/>




Page: 1 2

Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:
(Date:12/22/2014)... LENEXA, Kan. (PRWEB) December 22, 2014 ... it will add a subscription option to their ad ... for report writing services. Customers can sign up for ... report writing hours each month at a deeply discounted ... pricing tiers, and each has a progressively discounted rate. ...
(Date:12/22/2014)... December 22, 2014 On December 22, ... by Pastor Gordon Cashwell for an episode to celebrate ... Gordon, “Why is it so important to you that ... Cashwell replies, “We all should respect who Jesus was. ... founded on Christian beliefs. That means that on Jesus’ ...
(Date:12/22/2014)... Harrisburg, NC (PRWEB) December 22, 2014 ... contain the current Ebola virus epidemic are ... by U.S. government agencies, nongovernmental organizations (NGOs) ... solutions remains ongoing, healthcare workers, emergency responders, ... advanced technologies such as the CmTP ...
(Date:12/22/2014)... -- A new vaccine created to fight an illness ... protect livestock and even humans from similar brain infections, ... deer from becoming infected by the incurable brain disorder ... in the Dec. 21 online edition of the journal ... mysterious infectious particles known as prions that go rogue. ...
(Date:12/22/2014)... 22, 2014 The Bob Woodruff ... having invested more than $5 million in programs ... and their families. , This includes $1.3 million ... nonprofits, helping with: veteran entrepreneurship; community impact; vocational ... for severely injured veterans. , “The needs of ...
Breaking Medicine News(10 mins):Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7
... boceprevir has been available since the middle of 2011 ... 1. In an early benefit assessment pursuant to the ... Products" (AMNOG), the German Institute for Quality and Efficiency ... whether boceprevir offers added benefit in comparison with the ...
... N.Y. Researchers at Rensselaer Polytechnic Institute have developed ... disease. The surprisingly simple process was used to make ... to Alzheimer,s disease. , The process is reported in ... Proceedings of the National Academy of Sciences ( ...
... , THURSDAY, Nov. 8 (HealthDay News) -- Women aged 40 ... do themselves more harm than good, British researchers report. ... at the Wessex Institute at the University of Southampton, said ... those who receive diagnoses that turn out to be false ...
... increased in mothers postpartum, suggesting a potential new population ... cohort study. In the joint study between ... Anglia, researchers analyzed data on all women with pregnancies ... Database, which contains records from 460 practices across the ...
... Many Americans who experience acute kidney injury that does not ... year, which suggests that doctors need to do more to ... Acute kidney injury, an abrupt or rapid decline in kidney ... is caused by medical or surgical complications that deprive the ...
... Societies for Experimental Biology (FASEB) is pleased to announce ... for Glycobiology and the Society for Pediatric Research, which ... 2012. "These are very dynamic groups representing extremely important ... them as members," said FASEB President Joseph C. LaManna, ...
Cached Medicine News:Health News:Boceprevir: Indication of added benefit for specific patients 2Health News:Boceprevir: Indication of added benefit for specific patients 3Health News:Researchers design Alzheimer's antibodies 2Health News:British Study Suggests Mammograms Do More Harm Than Good 2Health News:British Study Suggests Mammograms Do More Harm Than Good 3Health News:Diagnosis of tuberculosis is increased in postpartum women 2Health News:Few With Acute Kidney Injury See Specialists, Study Finds 2
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
(Date:12/19/2014)... Friday, December 19 edition of USA ... features Konica Minolta, the company announced today. The supplement will focus ... organizations. In addition to the print section that ... New York , Chicago , ... Minneapolis and San Francisco , a ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2
... Feb. 16, 2012 Mylan Inc. (Nasdaq: ... ) today announced that Meridian Medical Technologies, a Pfizer ... and Sanofi-Aventis that will resolve pending patent litigation related ... epinephrine auto-injector known as e-cue™, which will be manufactured ...
... Acknowledging the importance of dedicated information management systems ... demonstrate the most recent version of its MOSAIQ® ... and Management Systems Society,s 2012 conference (HIMSS12), Feb. ... is a comprehensive OIS that centralizes traditional radiation ...
Cached Medicine Technology:Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 2Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 3Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 4Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 5Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting 2
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
Direct antigen rapid immunoassay for the detection of Shiga toxin-producing E. coli 0157, which aids in the diagnosis of E. coli 0157:H7 infection...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Inquire...
Medicine Products: